Search results | malaria

Reports

Malaria Partnering

The Malaria Partnering provides understanding and access to the malaria partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Mylan bids on old drugs of GSK

Several companies, including Mylan , have submitted a second round of bidding for a portfolio of older GlaxoSmithKline drugs.  

Co- development

Two parties join together to develop a technology, compound or product jointly.

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Top biopharma recipients of NIH funding 2013 and their partnering activity

Which companies earned the most grant funding so far in 2013 from the National institutes of Health and its subsidiaries such NIAID, NINDS NCI and so on

Industry trends in vaccine dealmaking – 2007 to 2013

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity

Pharma news: Pfizer, Hospira likely shoppers for Indian injectables star Agila

A shortage of injectable drugs in the U.S. means India’s Strides Arcolab Ltd. (STR) could sell a division that makes generic cancer treatments and antibiotics for more than the entire company’s market value.

Smaller biotech comapnies partner to tackle neglected diseases

Small- to medium-sized  biotech companies are stepping up alongside big pharma to develop treatments and diagnostics for neglected diseases such as tuberculosis, malaria and dengue fever, which because they typically affect impoverished third-world countries have been considered noncommercial markets

Non-profits share valuable lessons on efficient drug development

When Tachi Yamada left the pharmaceutical industry in 2006 to become head of global health at the Bill & Melinda Gates Foundation, he was sceptical about the non-profit medical partnerships that the businessman-turned-philanthropist had been funding extensively.

Events

Sorry, your search returned no results.


Deals

Co-development agreement for malaria vaccine

ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).

Alliance pharma partners to acquires antimalarial brands from AstraZeneca UK

AstraZeneca UK, a big pharma company has sold its three  antimalarial brands to Alliance Pharma in a pharma partners agreement, for an initial consideration of £4.2m.

Merck & Co. collaborate with Path and New York University to research potential malaria vaccine

Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced today by global leaders in malaria research and vaccine development.

Pfizer and Medicines For Malaria Venture seek to expand fight against malaria with intermittent preventive treatment option for pregnant women

Pfizer plans to seek marketing authorization in selected malaria-endemic African countries where, with MMV, it will seek to introduce the use of this important potential therapy to improve pregnancy outcomes and neonatal survival.

Crucell in collaboration with GlaxoSmithKline on second generation malaria vaccine candidate

Crucell will contribute its recombinant malaria vaccine candidate, Ad35-CS, based on Crucell’s AdVac technology and PER.C6 manufacturing platform and GSK will contribute its late stage malaria vaccine candidate RTS,S/AS. Financial details of the agreement were not disclosed.

Kymab raises $40 million in series B financing

Kymab has successfully raised US$40 million in a Series B financing.

M&A news: GlaxoSmithKline acquires Okairos in $324 million deal

M&A news: GlaxoSmithKline has acquired Okairos, a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash.

Hawaii Biotech enters into pharma licensing pact with Merck

Hawaii Biotech has acquired a family of patents to West Nile virus vaccine technology in a  nonexclusive pharma licensing pact related technologies from Merck, a big pharma company.

Big pharma alliances for infectious diseases drug development

Five Japanese life sciences giants pharma alliances with the Bill and Melinda Gates Foundation and Japan’s government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries.

Series C financing helps Genocea Biosciences raise $30 million

Genocea Biosciences has raised $30 million in a Series C financing round.